Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.

Abstract

In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with human immunodeficiency virus infection, the mean changes in low-density lipoprotein cholesterol were -5.3% (-11 mg/dL) and +5.5% (+4 mg/dL) with ezetimibe treatment and placebo, respectively (P = .04). Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin.

DOI: 10.1086/592116
020402011201220132014201520162017
Citations per Year

66 Citations

Semantic Scholar estimates that this publication has 66 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Wohl2008EzetimibeAR, title={Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.}, author={David A Wohl and David D Waters and Ross J. Simpson and Susan Richard and Amanda Schnell and Sonia Napravnik and Jessica R Keys and Joseph J Eron and Priscilla Ying Hsue}, journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America}, year={2008}, volume={47 8}, pages={1105-8} }